Substance Use Disorders

  • Laura Orsolini
  • Gabriele Duccio Papanti
  • Cesario Bellantuono
  • Domenico De Berardis
  • Fabrizio Schifano


Epidemiological data revealed an increasing consume of both ‘legal’ (i.e. tobacco, alcohol) and illegal substances amongst women of childbearing age, during the last decades, with a subsequent increasing risk of teratogenesis and perinatal complications for foetus of pregnant women exposed to substances of abuse/misuse. The early identification and management of women at risk of substance use disorders (SUDs) in pregnancy may help clinicians in promptly applying specifically targeted harm reduction interventions. The present chapter aims at providing a comprehensive overview on birth defects, foetal malformations, teratogenic risk and perinatal complications related to the consumption of cannabinoids, opioids and psychostimulant drugs during pregnancy. Practical recommendations on how to manage a pregnant woman with a SUD (with and/or without a comorbid psychiatric disorder) have been as well here provided, from a pharmacological and nonpharmacological point of view.


Substance use disorders Pregnancy Perinatal period Cannabinoids Cocaine Opioids Substances 


  1. 1.
    De Santis M, De Luca C, Mappa I, Quattrocchi T, Angelo L, Cesari E. Smoke, alcohol consumption and illicit drug use in an Italian population of pregnant women. Eur J Obstet Gynecol Reprod Biol. 2011;159(1):106–10. Scholar
  2. 2.
    Australian Institute of Health and Welfare. 2010 National Drug Strategy Household Survey report. Drug statistics series no. 25. Cat. no. PHE 145. Canberra: AIHW; 2011.Google Scholar
  3. 3.
    United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. National survey on drug use and health, 2007. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [Distributor]; 2015. Scholar
  4. 4.
    National Center for Chronic Disease Prevention and Health Promotion; Office on Smoking and Health (U.S.). How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the surgeon general. Atlanta, GA: Centers for Disease Control and Prevention US; 2010.Google Scholar
  5. 5.
    Rodgman A, Perfetti TA. The chemical components of tobacco and tobacco smoke. 1st ed. Boca Raton, FL: CRC Press, Taylor & Francis Group; 2009.Google Scholar
  6. 6.
    Honein MA, Paulozzi LJ, Watkins ML. Maternal smoking and birth defects: validity of birth certificate data for effect estimation. Public Health Rep. 2001;116:327–55.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Haustein K. Cigarette smoking, nicotine and pregnancy. Int J Clin Pharmacol Ther. 1999;37:417–27.PubMedGoogle Scholar
  8. 8.
    Wakschlag LS, Pickett KE, Cook E Jr, Benowitz NL, Leventhal BL. Maternal smoking during pregnancy and severe antisocial behavior in offspring: a review. Am J Public Health. 2002;92:966–74.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Frary C, Johnson R, Wang M. Food sources and intakes of caffeine in the diets of persons in the United States. J Am Diet Assoc. 2005;105:110–3.PubMedGoogle Scholar
  10. 10.
    Kaiser L, Allen L. Position of the American Dietetic Association: nutrition and lifestyle for a healthy pregnancy outcome. J Am Diet Assoc. 2008;108:553–61.PubMedGoogle Scholar
  11. 11.
    Loomans EM, Hofland L, Van der Stelt O, Van der Wal MF, Koot HM, Van den Bergh BR, Vrijkotte TGM. Caffeine intake during pregnancy and risk of problem behavior in 5- to 6-year-old children. Pediatrics. 2012;130:e305–13.PubMedGoogle Scholar
  12. 12.
    United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Center for Behavioral Health Statistics and Quality. National survey on drug use and health, 2013. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [Distributor]; 2015. Scholar
  13. 13.
    Lamy S, Thibaut F. Psychoactive substance use during pregnancy: a review [article in French]. Encéphale. 2010;36:33–8. Scholar
  14. 14.
    Gyarmathy VA, Giraudon I, Hedrich D, Montanari L, Guarita B, Wiessing L. Drug use and pregnancy – challenges for public health. Euro Surveill. 2009;14(9):33–6.PubMedGoogle Scholar
  15. 15.
    Pichini S, Puig C, Zuccaro P, Marchei E, Pellegrini M, Murillo J, Vall O, Pacifici R, García-Algar O. Assessment of exposure to opiates and cocaine during pregnancy in a Mediterranean city: preliminary results of the “Meconium Project”. Forensic Sci Int. 2005;153(1):59–65.Google Scholar
  16. 16.
    Goel N, Beasley D, Rajkumar V, Banerjee S. Perinatal outcome of illicit substance use in pregnancy—comparative and contemporary socio-clinical profile in the UK. Eur J Pediatr. 2011;170(2):199–205. Scholar
  17. 17.
    Regier DA, Farmer ME, Rae DS, Myers JK, Kramer M, Robins LN, George LK, Karno M, Locke BZ. One-month prevalence of mental disorders in the United States and sociodemographic characteristics: the epidemiologic catchment area study. Acta Psychiatr Scand. 1993;88(1):35–47.PubMedGoogle Scholar
  18. 18.
    Kandel DB, Huang FY, Davies M. Comorbidity between patterns of substance use dependence and psychiatric syndromes. Drug Alcohol Depend. 2001;64(2):233–41.PubMedGoogle Scholar
  19. 19.
    Fitzsimons HE, Tuten M, Vaidya V, Jones HE. Mood disorders affect drug treatment success of drug-dependent pregnant women. J Subst Abus Treat. 2007;32(1):19–25.Google Scholar
  20. 20.
    Martin PR, Arria AM, Fischer G, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Selby P, Jones HE. Psychopharmacologic management of opioid-dependent women during pregnancy. Am J Addict. 2009;18:148–56. Scholar
  21. 21.
    Unger AS, Martin PR, Kaltenbach K, Stine SM, Heil SH, Jones HE, Arria AM, Coyle MG, Selby P, Fischer G. Clinical characteristics of central European and North American samples of pregnant women screened for opioid agonist treatment. Eur Addict Res. 2010;16(2):99–107. Scholar
  22. 22.
    Greenfield SF, Back SE, Lawson K, Brady KT. Substance abuse in women. Psychiatr Clin North Am. 2010;33(2):339–55. Scholar
  23. 23.
    Pajulo M, Savonlahti E, Sourander A, Helenius H, Piha J. Antenatal depression, substance dependency and social support. J Affect Disord. 2001;65(1):9–17.PubMedGoogle Scholar
  24. 24.
    Najavits LM, Weiss RD, Shaw SR. The link between substance abuse and posttraumatic stress disorder in women. A research review. Am J Addict. 1997;6(4):273–83.PubMedGoogle Scholar
  25. 25.
    Davitian C, Uzan M, Tigaizin A, Ducarme G, Dauphin H, Poncelet C. Maternal cannabis use and intra-uterine growth restriction. Gynecol Obstet Fertil. 2006;34(7–8):632–7.PubMedGoogle Scholar
  26. 26.
    Westfall RE, Janssen PA, Lucas P, Capler R. Survey of medicinal cannabis use among childbearing women: patterns of its use in pregnancy and retroactive self-assessment of its efficacy against ‘morning sickness’. Complement Ther Clin Pract. 2006;12(1):27–33.PubMedGoogle Scholar
  27. 27.
    Cox S, Johnson CH, Meikle S, et al. Trends in rates of hospitalization with a diagnosis of substance abuse among reproductive-age women, 1998 to 2003. Womens Health Issues. 2007;17(2):75–83. doi:S1049-3867(07)00026-6[Pii]PubMedGoogle Scholar
  28. 28.
    Pan IJ, Yi HY. Prevalence of hospitalized live births affected by alcohol and drugs and parturient women diagnosed with substance abuse at liveborn delivery: United States, 1999–2008. Mater Child Health J. 2013;17(4):667–76. Scholar
  29. 29.
    Creanga AA, Sabel JC, Ko JY, Wasserman CR, Shapiro-Mendoza CK, Taylor P, Barfield W, Cawthon L, Paulozzi LJ. Maternal drug use and its effect on neonates: a population-based study in Washington state. Obstet Gynecol. 2012;119(5):924–33. Scholar
  30. 30.
    Pertwee RG. Receptors targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem. 2010;17(14):1360–81.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Hanuš LO. Discovery and isolation of anandamide and other endocannabinoids. Chem Biodivers. 2007;4(8):1828–41.PubMedGoogle Scholar
  32. 32.
    Al-Hayani A, Wease KN, Ross RA, Pertwee RG, Davies SN. The endogenous cannabinoid anandamide activates vanilloid receptors in the rat hippocampal slice. Neuropharmacology. 2001;41(8):1000–5.PubMedGoogle Scholar
  33. 33.
    van Gelder MM, Reefhuis J, Caton AR, Werler MM, Druschel CM, Roeleveld N. Maternal periconceptional illicit drug use and the risk of congenital malformations. Epidemiology. 2008;20:60.Google Scholar
  34. 34.
    Fergusson DM, Horwood LJ, Northstone K, ALSPAC Study Team. Avon longitudinal study of pregnancy and childhood. Maternal use of cannabis and pregnancy outcome. BJOG. 2002;109(1):21–7.PubMedGoogle Scholar
  35. 35.
    Greenland S, Staisch KJ, Brown N, Gross SJ. The effects of marijuana use during pregnancy: I. A preliminary epidemiologic study. Am J Obstet Gynecol. 1982;143(4):408–13.PubMedGoogle Scholar
  36. 36.
    Orsolini L, Papanti D, Corkery J, De Luca MA, Cadoni C, Di Chiara G, Schifano F. Is there a teratogenicity risk associated with cannabis and synthetic cannabimimetics’ (‘spice’) intake? CNS Neurol Disord Drug Targets. 2017;16(5):585–91. Scholar
  37. 37.
    Cornelius MD, Goldschmidt L, Day NL, Larkby C. Alcohol tobacco and marijuana use among pregnant teenagers: 6-year follow- up of offspring growth effects. Neurotoxicol Teratol. 2002;24(6):703–10.PubMedGoogle Scholar
  38. 38.
    Day NL, Richardson GA, Goldschmidt L, Robles N, Taylor PM, Stoffer DS, Cornelius MD, Geva D. Effect of prenatal marijuana exposure on the cognitive development of offspring at age three. Neurotoxicol Teratol. 1994;16(2):169–75.PubMedGoogle Scholar
  39. 39.
    Richardson GA, Day NL, Goldschmidt L. Prenatal alcohol, marijuana, and tobacco use: infant mental and motor development. Neurotoxicol Teratol. 1995;17(4):79–487.Google Scholar
  40. 40.
    Zuckerman B, Frank DA, Hingson R, Amaro H, Levenson SM, Kayne H, Parker S, Vinci R, Aboagye K, Fried LE. Effects of maternal marijuana and cocaine use on fetal growth. N Engl J Med. 1989;320(12):762–8.PubMedGoogle Scholar
  41. 41.
    El Marroun H, Hudziak JJ, Tiemeier H, Creemers H, Steegers EA, Jaddoe VW. Intrauterine cannabis exposure leads to more aggressive behavior and attention problems in 18-month-old girls. Drug Alcohol Depend. 1990;118:470.Google Scholar
  42. 42.
    Fried PA, Makin JE. Neonatal behavioral correlates of prenatal exposure to marihuana, cigarettes and alcohol in a low risk population. Neurotoxicol Teratol. 1987;9:1.PubMedGoogle Scholar
  43. 43.
    Fried PA, Watkinson B. Cognitive development: memory and verbal outcome measures were negatively associated with prenatal marijuana use 36- and 48-month neurobehavioral follow-up of children prenatally exposed to marijuana, cigarettes, and alcohol. J Dev Behav Pediatr. 1990;11:49.PubMedGoogle Scholar
  44. 44.
    Goldschmidt L, Richardson GA, Willford J, Day NL. Prenatal marijuana exposure and intelligence test performance at age 6. J Am Acad Child Adolesc Psychiatry. 2008;47:254.PubMedGoogle Scholar
  45. 45.
    Huizink AC, Mulder EJH. Maternal smoking, drinking or cannabis use during pregnancy and neurobehavioral and cognitive functioning in human offspring. Neurosci Biobehav Rev. 2006;30:24.PubMedGoogle Scholar
  46. 46.
    Noland JS, Singer LT, Short EJ, Minnes S, Arendt RE, Kirchner HL, Bearer C. Prenatal drug exposure and selective attention in preschoolers. Neurotoxicol Teratol. 2005;27:429.PubMedGoogle Scholar
  47. 47.
    Stein MT, Drahota A, Chavira DA. Ian: a 7-year old with prenatal drug exposure and early exposure to family violence. J Dev Behav Pediatr. 2008;29:512.PubMedGoogle Scholar
  48. 48.
    Fried PA, Watkinson B. Differential effects on facets of attention in adolescents prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol. 2001;23:421–30.PubMedGoogle Scholar
  49. 49.
    Goldschmidt L, Day NL, Richardson GA. Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol Teratol. 2000;22(3):325–36.PubMedGoogle Scholar
  50. 50.
    Richardson GA, Ryan C, Willford J, Day NL, Goldschmidt L. Prenatal alcohol and marijuana exposure: effects on neuropsychological outcomes at 10 years. Neurotoxicol Teratol. 2002;24(3):309–20.PubMedGoogle Scholar
  51. 51.
    Gray KA, Day NL, Leech S, Richardson GA. Prenatal marijuana exposure: effect on child depressive symptoms at ten years of age. Neurotoxicol Teratol. 2005;27(3):439–48.PubMedGoogle Scholar
  52. 52.
    SAMHSA. OoAS: the DASIS report: cocaine route of administration trends: 1995–2005. Substance Abuse and Mental Health Services Administration: Rockville, MD; 2007.Google Scholar
  53. 53.
    Blakeslee S. Crack’s toll among babies: a joyless view, even of toys. New York Times. 17 Sep 1989.Google Scholar
  54. 54.
    Malanga CJ, Kosofsky BE. Mechanisms of action of drugs of abuse on the developing fetal brain. Clin Perinatol. 1999;26:17–37.PubMedGoogle Scholar
  55. 55.
    Behnke M, Eyler FD, Warner TD, Garvan CW, Hou W, Wobie K. Outcome from a prospective, longitudinal study of prenatal cocaine use: preschool development at 3 years of age. J Pediatr Psychol. 2006;31:41–9.PubMedGoogle Scholar
  56. 56.
    Minnes S, Singer LT, Arendt R, Satayathum S. Effects of prenatal cocaine/polydrug use on maternal–infant feeding interactions during the first year of life. Dev Behav Pediatr. 2005;26:194–200.Google Scholar
  57. 57.
    Frank DA, Augustyn M, Knight WG, Pell T, Zuckerman B. Growth, development, and behavior in early childhood following prenatal cocaine exposure: a systematic review. JAMA. 2001;285:1613–25.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Singer LT, Arendt R, Minnes S, Farkas K, Salvator A. Neurobehavioral outcomes of cocaine-exposed infants. Neurotoxicol Teratol. 2000;22:653–66.PubMedGoogle Scholar
  59. 59.
    Zuckerman B, Frank DA, Mayes L. Cocaine-exposed infants and developmental outcomes: “crack kids” revisited. JAMA. 2002;287:1990–1.PubMedGoogle Scholar
  60. 60.
    Bada HS, Das A, Bauer CR, Shankaran S, Lester BM, Gard CC, Wright LL, Lagasse L, Higgins R. Low birth weight and preterm births: etiologic fraction attributable to prenatal drug exposure. J Perinatol. 2005;25:631–7.PubMedGoogle Scholar
  61. 61.
    Singer LT, Salvator A, Arendt R, Minnes S, Farkas K, Kliegman R. Effects of cocaine/polydrug exposure and maternal psychological distress on infant birth outcomes. Neurotoxicol Teratol. 2002;24(2):127–35.PubMedGoogle Scholar
  62. 62.
    Bandstra ES, Vogel AL, Morrow CE, Xue L, Anthony JC. Severity of prenatal cocaine exposure and child language functioning through age seven years: a longitudinal latent growth curve analysis. Subst Use Misuse. 2004;39:25–59.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Morrow CE, Bandstra ES, Anthony JC, Ofir AY, Xue L, Reyes MB. Influence of prenatal cocaine exposure on early language development: longitudinal findings from four months to three years of age. J Dev Behav Pediatr. 2003;24:39–50.PubMedPubMedCentralGoogle Scholar
  64. 64.
    Singer LT, Arendt RA, Minnes S, Salvator A, Siegel AC, Lewis BA. Developing language skills of cocaine-exposed infants. Pediatrics. 2001;107:1057–64.PubMedGoogle Scholar
  65. 65.
    Andrade C. Risk of major congenital malformations associated with the use of methylphenidate or amphetamines in pregnancy. J Clin Psychiatry. 2018;79(1):18f12108.PubMedGoogle Scholar
  66. 66.
    Cohen JM, Hernández-Díaz S, Bateman BT, Park Y, Desai RJ, Gray KJ, Patorno E, Mogun H, Huybrechts KF. Placental complications associated with psychostimulant use in pregnancy. Obstet Gynecol. 2017;130:1192–201. Scholar
  67. 67.
    Moore DG, Turner JD, Parrott AC, Goodwin JE, Fulton SE, Min MO, Fox HC, Braddick FM, Axelsson EL, Lynch S, Ribeiro H, Frostick CJ, Singer LT. During pregnancy, recreational drug-using women stop taking ecstasy (3,4-methylenedioxy-N-methylamphetamine) and reduce alcohol consumption but continue to smoke tobacco and cannabis initial findings from the Development and Infancy Study. J Psychopharmacol. 2010;24:1403–10. Scholar
  68. 68.
    Fisk JE, Montgomery C, Wareing M, Murphy PN. Reasoning deficits in ecstasy (MDMA) polydrug users. Psychopharmacology. 2005;181:550–9.PubMedGoogle Scholar
  69. 69.
    Rendell PG, Gray TJ, Henry JD, Tolan A. Prospective memory impairment in “ecstasy” (MDMA) users. Psychopharmacology. 2007;194:497–504.PubMedGoogle Scholar
  70. 70.
    Rodgers J. Cognitive performance amongst recreational users of “ecstasy”. Psychopharmacology. 2000;151:19–24.PubMedGoogle Scholar
  71. 71.
    Rodgers J, Buchanan T, Scholey AB, Heffernan TM, Ling J, Parrott AC. Patterns of drug use and the influence of gender on self-reports of memory ability in ecstasy users: a web based study. J Psychopharmacol. 2003;17:379–86.Google Scholar
  72. 72.
    Barr AM, Panenka WJ, MacEwan W, Thornton AE, Lang DJ, Honer WG, Lecomte T. The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci. 2006;31:301–13.PubMedPubMedCentralGoogle Scholar
  73. 73.
    Cass WA. Decreases in evoked overflow of dopamine in rat striatum after neurotoxic doses of metham-phetamine. J Pharmacol Exp Ther. 1997;280:105–13.PubMedGoogle Scholar
  74. 74.
    Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH, Grant I. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev. 2007;17:275–97.PubMedGoogle Scholar
  75. 75.
    Billing L, Eriksson M, Larsson G, Zetterström R. Amphetamine addiction and pregnancy. III. One year follow-up of the children. Psychosocial and pediatric aspects. Acta Paediatr Scand. 1980;69:675–80.PubMedGoogle Scholar
  76. 76.
    Catanzarite VA, Stein DA. ‘Crystal’ and pregnancy—methamphetamine-associated maternal deaths. West J Med. 1995;162:454–7.PubMedPubMedCentralGoogle Scholar
  77. 77.
    Dixon SD, Bejar R. Echoencephalographic findings in neonates associated with maternal cocaine and methamphetamine use: incidence and clinical correlates. J Pediatr. 1989;115:770–8.PubMedGoogle Scholar
  78. 78.
    Eriksson M, Larsson G, Winbladh B, Zetterström R. The influence of amphetamine addiction on pregnancy and the newborn infant. Acta Paediatr Scand. 1978;67:95–9.PubMedGoogle Scholar
  79. 79.
    Eriksson M, Larsson G, Zetterström R. Amphetamine addiction and pregnancy. II. Pregnancy, delivery, and the neonatal period. Socio-medical aspects. Acta Obstet Gynecol Scand. 1981;60:253–9.PubMedGoogle Scholar
  80. 80.
    Plessinger MA. Prenatal exposure to amphetamines. Risks and adverse outcomes in pregnancy. Obstet Gynecol Clin N Am. 1998;25:119–38.Google Scholar
  81. 81.
    van Tonningen-van Driel MM, Garbis-Berkvens JM, Reuvers-Lodwijks WE. Pregnancy outcome after ecstasy use, 43 cases followed by the Teratology Information Service of the National Institute for Public Health and Environment (RIVM). Ned Tijdschr Geneeskd. 1999;143:27–31. (Dutch).Google Scholar
  82. 82.
    Bronson ME, Jiang W, Clark CR, DeRuiter J. Effects of designer drugs on the chicken embryo and 1-day-old chicken. Brain Res Bull. 1994;34:143–50.PubMedGoogle Scholar
  83. 83.
    Smith L, Yonekura ML, Wallace T, Berman N, Kuo J, Berkowitz C. Effects of prenatal methamphetamine exposure on fetal growth and drug withdrawal symptoms in infants born at term. J Dev Behav Pediatr. 2003;24:17–23.PubMedGoogle Scholar
  84. 84.
    Huybrechts KF, Bateman BT, Desai RJ, Hernandez-Diaz S, Rough K, Mogun H, Kerzner LS, Davis JM, Stover M, Bartels D, Cottral J, Patorno E. Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study. BMJ. 2017;358:3326. Scholar
  85. 85.
    Dryden C, Young D, Hepburn M, Mactier H. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. BJOG. 2009;116(5):665–71.PubMedGoogle Scholar
  86. 86.
    Hwang CS, Kang EM, Kornegay CJ, Staa JA, Jones CM, McAninch JK. Trends in the Concomitant Prescribing of Opioids and Benzodiazepines, 2002–2014. Am J Prev Med. 2016;51(2):151–60.PubMedGoogle Scholar
  87. 87.
    Wachman EM, Newby PK, Vreeland J, Byun J, Bonzagni A, Bauchner H, Philipp BL. The relationship between maternal opioid agonists and psychiatric medications on length of hospitalization for neonatal abstinence syndrome. J Addict Med. 2011;5(4):293–9.PubMedGoogle Scholar
  88. 88.
    CSAT (Center for Substance Abuse Treatment). Medication-assisted treatment for opioid addiction during pregnancy. In: CSAT, editor. Medication-assisted treatment for opioid addiction in opioid treatment programs. Treatment improvement protocol (TIP) series, no. 43. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2005. p. 211–24.Google Scholar
  89. 89.
    Kaltenbach K, Finnegan LP. Developmental outcome of children born to methadone maintained women: a review of longitudinal studies. Neurobehav Toxicol Teratol. 1984;6:271–5.PubMedGoogle Scholar
  90. 90.
    Bracken MB, Holford TR. Exposure to prescribed drugs in pregnancy and association with congenital malformations. Obstet Gynecol. 1981;58:336–44.PubMedGoogle Scholar
  91. 91.
    Jick H, Holmes LB, Hunter JR, Madsen S, Stergachis A. First-trimester drug use and congenital disorders. JAMA. 1981;246:343–6.PubMedGoogle Scholar
  92. 92.
    Broussard CS, Rasmussen SA, Reefhuis J, Friedman JM, Jann MW, Riehle-Colarusso T, et al. Maternal treatment with opioid analgesics and risk for birth defects. National birth defects prevention study. Am J Obstet Gynecol. 2011;204:314.e1–11.Google Scholar
  93. 93.
    Zierler S, Rothman KJ. Congenital heart disease in relation to maternal use of Bendectin and other drugs in early pregnancy. N Engl J Med. 1985;313:347–52.PubMedGoogle Scholar
  94. 94.
    Nezvalova-Henriksen K, Spigset O, Nordeng H. Effects of codeine on pregnancy outcome: results from a large population-based cohort study. Eur J Clin Pharmacol. 2011;67:1253–61.PubMedPubMedCentralGoogle Scholar
  95. 95.
    Shaw GM, Malcoe LH, Swan SH, Cummins SK, Schulman J. Congenital cardiac anomalies relative to selected maternal exposures and conditions during early pregnancy. Eur J Epidemiol. 1992;8:757–60.PubMedGoogle Scholar
  96. 96.
    Yazdy MM, Mitchell AA, Tinker SC, Parker SE, Werler MM. Periconceptional use of opioids and the risk of neural tube defects. Obstet Gynecol. 2013;122:838–44.PubMedPubMedCentralGoogle Scholar
  97. 97.
    Metz V, Köchl B, Fischer G. Should pregnant women with substance use disorders be managed differently? Neuropsychiatry (Lond). 2012;2(1):29–41.Google Scholar
  98. 98.
    Gérardin M, Victorri-Vigneau C, Louvigné C, Rivoal M, Jolliet P. Management of cannabis use during pregnancy: an assessment of healthcare professionals’ practices. Pharmacoepidemiol Drug Saf. 2011;20(5):464–73. Scholar
  99. 99.
    The Centre for Addiction and Mental Health (CAMH). 2012. Accessed 25 Aug 2018.
  100. 100.
    Rayburn WF, Bogenschutz MP. Pharmacotherapy for pregnant women with addictions. Am J Obstet Gynecol. 2004;191:1885–97.PubMedGoogle Scholar
  101. 101.
    SAMHSA. SAMHSA website. 2010. or at Accessed 6 May 2010.
  102. 102.
    McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf. 2009;32(11):1089–96.PubMedGoogle Scholar
  103. 103.
    Good MM, Solt I, Acuna JG, Rotmensch S, Kim MJ. Methamphetamine use during pregnancy: maternal and neonatal implications. Obstet Gynecol. 2010;116(2 Pt 1):330–4.PubMedGoogle Scholar
  104. 104.
    Winklbaur-Hausknost B, Jagsch R, Graf-Rohrmeister K, Unger A, Baewert A, Langer M, Thau K, Fischer G. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Hum Psychopharmacol. 2013;28(1):15–24. Scholar
  105. 105.
    British Columbia Centre on Substance Use, B.C. Ministry of Health, B.C. Ministry of Mental Health and Addictions, & Perinatal Services BC. A guideline for the clinical management of opioid use disorder—pregnancy supplement. 2018.
  106. 106.
    Minozzi S, Amato L, Bellisario C, Ferri M, Davoli M. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev. 2013;12:Cd006318.Google Scholar
  107. 107.
    WHO. WHO guidelines approved by the guidelines review committee. In: Clinical guidelines for withdrawal management and treatment of drug dependence in closed settings. Geneva: World Health Organization; 2009. Copyright (c) World Health Organization 2009.Google Scholar
  108. 108.
    Jones HE, Martin PR, Heil SH, Kaltenbach K, Selby P, Coyle MG, Stine SM, O’Grady KE, Arria AM, Fischer G. Treatment of opioid dependent pregnant women: clinical and research issues. J Subst Abus Treat. 2008;35(3):245–59.Google Scholar
  109. 109.
    Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O’Grady KE, Selby P, Martin PR, Fisher G. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320–31.PubMedPubMedCentralGoogle Scholar
  110. 110.
    Noormohammadi A, Forinash A, Yancey A, Crannage E, Campbell K, Shyken J. Buprenorphine versus methadone for opioid dependence in pregnancy. Ann Pharmacother. 2016;50(8):666–72.PubMedGoogle Scholar
  111. 111.
    Zedler BK, Mann AL, Kim MM, Amick HR, Joyce AR, Murrelle EL, Jones HE. Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child. Addiction. 2016;111(12):2115–28. Scholar
  112. 112.
    American Society of Addiction Medicine. Substance use, misuse, and use disorders during and following pregnancy, with an emphasis on opioids. 2017.
  113. 113.
    Wright TE, Terplan M, Ondersma SJ, Boyce C, Yonkers K, Chang G, Creanga AA. The role of screening, brief intervention, and referral to treatment in the perinatal period. Am J Obstet Gynecol. 2016;215(5):539–47.Google Scholar
  114. 114.
    Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry. 1996;153:592–606.PubMedGoogle Scholar
  115. 115.
    El Marroun H, Tiemeier H, Steegers EAP, Jaddoe VW, Hofman A, Verhulst FC, van den Brink W, Huizink AC. Intrauterine Cannabis exposure affects fetal growth trajectories: the Generation R Study. J Am Acad Child Adolesc Psychiatry. 2009;48:1173Y1181.Google Scholar
  116. 116.
    Hatch EE, Bracken MB. Effect of marijuana use in pregnancy on fetal growth. Am J Epidemiol. 1986;124(6):986–93.PubMedGoogle Scholar
  117. 117.
    Hayatbakhsh MR, Flenady VJ, Gibbons KS, Kingsbury AM, Hurrion E, Mamun AA, Najman JM. Birth outcomes associated with cannabis use before and during pregnancy. Pediatr Res. 2012;71(2):215–9. Scholar
  118. 118.
    Varner MW, Silver RM, Rowland Hogue CJ, Willinger M, Parker CB, Thorsten VR, Goldenberg RL, Saade GR, Dudley DJ, Coustan D, Stoll B, Bukowski R, Koch MA, Conway D, Pinar H, Reddy UM, Eunice Kennedy Shriver National Institute of Child Health and Human Development Stillbirth Collaborative Research Network. Association between stillbirth and illicit drug use and smoking during pregnancy. Obstet Gynecol. 2014;123(1):113–25. Scholar
  119. 119.
    van Gelder MM, Reefhuis J, Caton AR, Werler MM, Druschel CM, Roeleveld N, National Birth Defects Prevention Study. Characteristics of pregnant illicit drug users and associations between cannabis use and perinatal outcome in a population-based study. Drug Alcohol Depend. 2010;109(1–3):243–7. Scholar
  120. 120.
    Maeda A, Bateman BT, Clancy CR, Creanga AA, Leert LR. Opioid abuse and dependence during pregnancy: temporal trends and obstetrical outcomes. Anesthesiology. 2014;121(6):1158–65.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Laura Orsolini
    • 1
    • 2
    • 3
  • Gabriele Duccio Papanti
    • 2
  • Cesario Bellantuono
    • 4
  • Domenico De Berardis
    • 3
    • 5
    • 6
  • Fabrizio Schifano
    • 2
  1. 1.KOS Care S.r.L., Neomesia Mental HealthVilla Jolanda HospitalSciscianoItaly
  2. 2.Psychopharmacological, Drug Misuse and Novel Psychoactive Substances Research UnitSchool of Life and Medical Sciences, University of HertfordshireHatfieldUK
  3. 3.Polyedra ResearchTeramoItaly
  4. 4.DeGra Clinic for Perinatal Mental DisordersVeronaItaly
  5. 5.NHS, Department of Mental Health, Psychiatric Service of Diagnosis and TreatmentHospital “G. Mazzini”TeramoItaly
  6. 6.Department of Neurosciences and ImagingUniversity “G. D’Annunzio”ChietiItaly

Personalised recommendations